NASDAQ:EDITEditas Medicine Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Editas Medicine Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $27.07 -0.22 (-0.81 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$26.21Now: $27.07▼$27.8450-Day Range$20.61MA: $24.99▼$30.1052-Week Range$14.01Now: $27.07▼$34.37Volume1.03 million shsAverage Volume923,921 shsMarket Capitalization$1.49 billionP/E RatioN/ADividend YieldN/ABeta2 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingEditas Medicine has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.75, Editas Medicine has a potential upside of 39.5% from its current price of $27.07.Amount of Analyst CoverageEditas Medicine has only been the subject of 3 research reports in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesEditas Medicine has received 262 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEditas Medicine has received 363 “underperform” votes. (Add your “underperform” vote.)Community SentimentEditas Medicine has received 58.08% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote “Outperform” if you believe EDIT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EDIT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.94% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions81.93% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Editas Medicine are expected to decrease in the coming year, from ($3.00) to ($3.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -9.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -9.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 6.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.25 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EDIT Previous Symbol CUSIPN/A CIK1650664 Webwww.editasmedicine.com Phone617-401-9000Debt Debt-to-Equity Ratio0.09 Current Ratio6.17 Quick Ratio6.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20.53 million Price / Sales72.52 Cash FlowN/A Price / Cash FlowN/A Book Value$4.27 per share Price / Book6.34Profitability EPS (Most Recent Fiscal Year)($2.68) Net Income$-133,750,000.00 Net Margins-588.05% Return on Equity-63.21% Return on Assets-33.39%Miscellaneous Employees133 Outstanding Shares55,000,000Market Cap$1.49 billion Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:EDIT Rates by TradingView Receive EDIT News and Ratings via Email Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions How has Editas Medicine's stock been impacted by COVID-19 (Coronavirus)? Editas Medicine's stock was trading at $20.27 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EDIT stock has increased by 33.5% and is now trading at $27.07. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Editas Medicine? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Editas Medicine. When is Editas Medicine's next earnings date? Editas Medicine is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Editas Medicine. How were Editas Medicine's earnings last quarter? Editas Medicine Inc (NASDAQ:EDIT) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.79) by $0.10. The firm had revenue of $5.70 million for the quarter, compared to analysts' expectations of $6.73 million. Editas Medicine had a negative net margin of 588.05% and a negative return on equity of 63.21%. The business's revenue was up 171.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.60) earnings per share. View Editas Medicine's earnings history. What price target have analysts set for EDIT? 6 analysts have issued 1-year price targets for Editas Medicine's stock. Their forecasts range from $27.00 to $55.00. On average, they expect Editas Medicine's stock price to reach $37.75 in the next year. This suggests a possible upside of 39.5% from the stock's current price. View analysts' price targets for Editas Medicine. What are Wall Street analysts saying about Editas Medicine stock? Here are some recent quotes from research analysts about Editas Medicine stock: 1. According to Zacks Investment Research, "Editas' lead candidate EDIT-101, which uses CRISPR gene editing to treat LCA10, a genetic illness that causes blindness, is being developed in partnership with Allergan. The disease has a significant unmet need as no therapies are presently approved. A phase I/II dose escalation study on EDIT-101 initiated patient enrolment in July 2019. Editas has some high-profile collaborations with big pharma companies for its CRISPR technology, which provide research support and funds to pursue its pipeline development. It is also developing EDIT-301 for sickle cell disease and beta-thalassemia. However, due to lack of a marketed product, Editas is heavily dependent on its partners for collaboration revenues, which remains a concern. Shares have outperformed the industry in the past year." (1/14/2020) 2. Chardan Capital analysts commented, "We anticipate better visibility around potential timing of data readouts as dosing gets underway. Below, we highlight thoughts on what we know of the program thus far." (7/25/2019) Has Editas Medicine been receiving favorable news coverage? Media coverage about EDIT stock has trended somewhat negative this week, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Editas Medicine earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutEditas Medicine. Who are some of Editas Medicine's key competitors? Some companies that are related to Editas Medicine include Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), bluebird bio (BLUE), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Novavax (NVAX), Alector (ALEC), Fate Therapeutics (FATE) and Bill.com (RVMD). View all competitors. What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Intellia Therapeutics (NTLA), Micron Technology (MU), Alibaba Group (BABA), Square (SQ), Advanced Micro Devices (AMD), Shopify (SHOP), Intel (INTC) and Canopy Growth (CGC). Who are Editas Medicine's key executives? Editas Medicine's management team includes the following people: Dr. Charles Albright, Chief Scientific Officer (Age 61)Ms. Cynthia L. Collins, Interim CEO & Director (Age 61)Dr. Feng Zhang, Co-Founder & Scientific Advisory Board MemberDr. George M. Church, Co-Founder & Scientific Advisory Board Member (Age 65)Dr. J. Keith Joung, Co-Founder & Scientific Advisory Board Member When did Editas Medicine IPO? (EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. What is Editas Medicine's stock symbol? Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT." Who are Editas Medicine's major shareholders? Editas Medicine's stock is owned by many different institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (9.31%), Nikko Asset Management Americas Inc. (9.31%), Nikko Asset Management Americas Inc. (9.29%), BlackRock Inc. (7.62%), State Street Corp (3.69%) and Geode Capital Management LLC (1.43%). Company insiders that own Editas Medicine stock include Andrew A F Hack, Charles Albright, Cynthia Collins, Jessica Hopfield, Katrine Bosley and Vickesh Myer. View institutional ownership trends for Editas Medicine. Which major investors are selling Editas Medicine stock? EDIT stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Deutsche Bank AG, Viking Global Investors LP, Two Sigma Investments LP, BNP Paribas Arbitrage SA, BlackRock Inc., and UBS Group AG. Company insiders that have sold Editas Medicine company stock in the last year include Charles Albright, and Cynthia Collins. View insider buying and selling activity for Editas Medicine. Which major investors are buying Editas Medicine stock? EDIT stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Elmwood Wealth Management Inc., Geode Capital Management LLC, Nuveen Asset Management LLC, and Russell Investments Group Ltd.. View insider buying and selling activity for Editas Medicine. How do I buy shares of Editas Medicine? Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Editas Medicine's stock price today? One share of EDIT stock can currently be purchased for approximately $27.07. How big of a company is Editas Medicine? Editas Medicine has a market capitalization of $1.49 billion and generates $20.53 million in revenue each year. The company earns $-133,750,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Editas Medicine employs 133 workers across the globe. What is Editas Medicine's official website? The official website for Editas Medicine is www.editasmedicine.com. How can I contact Editas Medicine? Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]med.com. This page was last updated on 5/31/2020 by MarketBeat.com Staff
